Immunocompromised Cancer Patients May Benefit from Innovative Immunehydrogel Therapy

Cancer has long been known to compromise the immune system, affecting both the peripheral immune system and the local tumor microenvironment. Current immunotherapies have shown limited efficacy due to severe immunosuppression. However, researchers from Amrita Vishwa Vidyapeetham have made a groundbreaking discovery, developing an immunologically engineered injectable immunehydrogel (iHG) that can recruit immune cells away from the suppressed tumor microenvironment and peripheral organs. This novel therapy has been tested in a mouse melanoma model, eliciting a robust antitumor immune response through both innate and adaptive arms.

Key Takeaways:

• The new immunehydrogel therapy has shown promise in overcoming immunosuppression in cancer patients by recruiting immune cells away from the tumor microenvironment.
• The injectable hydrogel compositions were optimized to attract and activate dendritic cells, macrophages, monocytes, natural killer cells, B cells, and T cells via various signaling pathways.
• The therapy was tested in a mouse melanoma model, where it elicited a robust antitumor immune response through both innate and adaptive arms.
• The research suggests that the immunehydrogel therapy may be more effective as a single agent than when combined with anti-PD1 immune checkpoint antibodies.
• The innovative therapy has the potential to reprogram immune cells to overcome both local and systemic immunosuppression, making it an attractive option for cancer treatment.
• The research highlights the importance of engineering immunologically functional and injectable hydrogel niches as a new type of immunotherapeutics.

Statistics:

• The research was published in Advanced Therapeutics in 2025.
• The immunehydrogel therapy was tested in a mouse melanoma model, with the results showing a robust antitumor immune response.
• The therapy was optimized to attract and activate various types of immune cells, including dendritic cells, macrophages, and T cells.
• The study found that the immunehydrogel therapy may be more effective as a single agent than when combined with anti-PD1 immune checkpoint antibodies.
• The research has significant implications for the treatment of cancer, particularly in patients who are immunocompromised.

Sources:

• Injectable Immune-engineered Hydrogel Niche Remote From the Immune Suppressed Tumor Microenvironment for Cancer Immunotherapy. Advanced Therapeutics, 2025.
• NewsRx. Reports from Amrita Vishwa Vidyapeetham Provide New Insights into Vaccines (Injectable Immune-engineered Hydrogel Niche Remote From the Immune Suppressed Tumor Microenvironment for Cancer Immunotherapy). Vaccine Weekly. July 16, 2025; p 52.